The pediatric Chinese patent medicine market has shrunk TOP10 products who are the most resistant to stress?

Medical Network News, June 3, the annual "Children's Day" has arrived.
Under the influence of the epidemic in 2020, children's activities are basically limited to the two points and one line at home and school, plus the cross-infection of diseases after wearing masks The morbidity rate has been greatly reduced, and the parents' care is also more careful.
The children's resistance has improved, and the common diseases have been reduced correspondingly.
The market size of pediatric Chinese patent medicines ushered in a decline for the first time last year.
The market looks "depressed", but star pharmaceutical companies are still actively increasing their layout.
In the near future, Step Pharmaceutical plans to acquire Anyang Nuomei Pharmaceutical's exclusive variety Xiaoer Fuqi Zhixie San for 19 million yuan.
The company is expected to be in the field of pediatric Chinese patent medicines.
Add fierce generals.

 

The over 10 billion market has shrunk by nearly 3.
7 billion, but the retail subcategory has soared by 20%

 

Meinenet data shows that in 2020, the sales growth rate of pediatric Chinese patent medicines in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be -32.
34%.
The growth rate of the pharmacy terminal is -14.
94%, and the total market size has shrunk by nearly 3.
7 billion yuan from 2019.

 

　　Figure 1: The share of the seven subcategories of pediatric Chinese patent medicines in 2020 (unit: %)

　　Source: Mi Nei Net Database

 

　　In terms of subcategories, pediatric cold medications and pediatric cough and expectorant medications are the two subcategories with the largest proportions, both at the terminals of public medical institutions in China and physical pharmacies in cities in China, but they are also the two most affected by the epidemic.
Subcategory.
The growth rate of pediatric cold medicines in China's public medical institutions will be -36.
81% in 2020, and -19.
92% in physical pharmacies in Chinese cities; pediatric cold medicines will grow by -40.
12% in China's public medical institutions in 2020.
The growth rate of physical pharmacies in Chinese cities is -23.
32%.

 

　　Pediatric nutritional supplement medications have emerged in the physical pharmacies of Chinese cities.
The market share in 2020 is as high as 10.
88%, and the sales growth rate in the last three years is as high as 15.
46%, 14.
86%, and 20.
76%.

 

　　Figure 2: Sales of terminal pediatric nutritional supplements in physical pharmacies in cities in China (unit: 100 million yuan)

　　Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern

 

　　In recent years, with the improvement of living standards and the changes in people’s consumption outlook, more and more parents have begun to pay attention to children’s health issues, and they are paying more and more attention to children’s nutrition, and they are more willing to buy children’s growth.
Appropriate nutritional supplement products during the development process are conducive to the expansion of the pediatric nutritional supplement drug market; in addition, with the gradual refinement and improvement of prescription outflow policies, the full implementation in the future will further stimulate this category of products in the retail market Sales rose.

 

　　TOP10 products are exposed, these exclusive varieties are the most stress-resistant

 

　　Table 1: TOP10 products of pediatric Chinese patent medicine in 2020

　　Source: Mi Nei Net Database

 

　　In 2020, the threshold for the TOP10 products of pediatric Chinese patent medicines in public medical institutions in China is 130 million yuan (240 million yuan in 2019), and the only products exceeding 1 billion are Xiaoer Liaoqiao Qingre Granules; and the threshold for TOP10 pediatric Chinese patent medicines in Chinese urban physical pharmacies For 140 million yuan (160 million yuan in 2019), the sales of TOP1 product Longmu Zhuanggu pellets were 470 million yuan.

 

　　From the product point of view, Xiaoer Lianqiao Qingre Granules, Jinzhen Oral Liquid and Xiaoer Feire Kechuan Granules all appeared on the two lists.
It can be seen that these three products have become the backbone of the pediatric Chinese patent medicine market.
Among them, Jichuan Pharmaceutical’s exclusive product Xiaoer Liaoqiao Qingre Granules is as stable as Mount Tai.
This product is a large variety of over 1 billion, and it is mainly used to treat children with wind-heat and cold.
At present, the main battlefield is at the terminal of public medical institutions in China, under the background of the pressure of the environment.
, Still sits firmly on the TOP1 throne in 2020, and continues to maintain sales of about 300 million yuan in physical pharmacies in Chinese cities, and the TOP4 status remains unchanged.

 

　　Figure 3: The sales of Kaihoujian spray (child type) in the terminal of public medical institutions in China (unit: 100 million yuan)

　　Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

 

　　The sales of some products have achieved bucking growth.
At the terminal of public medical institutions in China, Guizhou Sanli Pharmaceutical’s Kai Throat Spray (children's type) is the only product on the TOP10 list with positive sales growth for three consecutive years.
This exclusive product is taken from the classic Miao medicine prescription.
Spray administration can directly act on the throat, tonsils and other lesions, reduce the liver burden of drug metabolism in children, and directly absorb, have fast onset, high curative effect, and short course of treatment.
Pharyngitis, tonsillitis, herpetic angina, oral ulcers and other common respiratory tract infections in children have obvious advantages.

 

　　Figure 4: Sales of Longmu Zhuanggu Granules in physical pharmacies in Chinese cities (unit: 100 million yuan)

　　Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern

 

　　In physical pharmacies in cities in China, Longmu Zhuanggu Granules, an exclusive product of Jianmin Pharmaceutical Group, has supported more than 90% of the market for pediatric supplementary nutrition drugs.
The sales growth rate from 2018 to 2020 is 16.
44% and 14.
54 respectively.
%, 20.
75%.
Longmu Zhuanggu granules are used to treat and prevent infantile rickets.
Jianmin Group mentioned in the annual report that in 2020, the company will vigorously promote lean production, control costs, improve quality, strengthen brand building, channel promotion, and optimize sales strategies to help realize products pay increment.

 

　　Although it is difficult to develop new drugs, Jichuan and Calabash are at the forefront

 

　　With the development of society and economy, the spectrum of children's diseases is constantly changing, but there is still a clear gap between the level of research and development of children's drugs in my country and the international level.
On the one hand, children’s drug clinical trials are very difficult, and the most prominent impact is the inability to recruit enough cases; on the other hand, there is a large gap in professional children’s drug clinical researchers, who are equipped with children’s medicine, pharmacy, nursing, ethics, Talents with knowledge and experience in psychology and other areas are obviously insufficient.
According to data from the MED2.
0 China Drug Evaluation Database of Meinenet , there are few pediatric Chinese patent medicines approved for marketing in recent years.
In 2019, Tasly and Fangsheng Pharmaceuticals were approved for one new drug, which is very encouraging in the industry.

 

　　Table 2: Status of pediatric Chinese patent medicine products approved for marketing in 2019

　　Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

 

　　Table 3: Some pediatric Chinese patent medicines that have been approved in the past five years and have started clinical trials

　　Source: China Drug Clinical Trial Publicity Library of Meinenet

 

　　Note: *is included in the priority review product

 

　　At present, a number of pediatric Chinese patent medicines under development have attracted the attention of the market: Xiao'er Soy Bean Curd is an exclusive product of Jichuan Pharmaceutical.
The granules that have been marketed have grown to over 1 billion products, and the syrup formulation is undergoing phase III clinical trials.
It is used for the syndrome of wind-heat and cold in children.

 

　　Another children’s drug star pharmaceutical company Hainan Huluwa Pharmaceutical Group also has a new drug in phase II clinical phase.
Xiaoer Malong Zhike Pingchuan Granules are intended to treat children with cough variant asthma (phlegm-heat accumulating lung syndrome); in addition, according to the company’s annual report It shows that Xiaoer Huaji Granules are also preparing for phase II clinical trials, which are intended to be used in children's digestion and Huaji related diseases.

 

　　Policy dividends help the growth of pediatric chemicals, and dosage form innovation will become a new trend

 

　　According to the "Research Report on my country’s Children’s Medicine Market (2021 Edition)" on Mynet, in the overall market of children’s medicines in my country, chemical drugs rely on their advantages of fast onset and clear mechanism of action.
In recent years, the market size has been rising.
The share has also increased to more than 60%, and the potential cannot be underestimated.

 

　　Several new policies were issued and implemented in 2020 to further stimulate the development of pediatric chemicals: The newly revised "Administrative Measures for Drug Registration" announced in March clearly stated that new varieties, dosage forms and specifications of children's drugs that meet the physiological characteristics of children can apply for priority Review and approval procedures; In June, CDE issued the "Guidelines for Pharmaceutical Development of Children's Drugs (Chemical Drugs) (Draft for Solicitation of Comments)" to provide R&D ideas and technical guidance for the pharmaceutical development of children's drugs; the "National Medical Insurance 2020" announced in August The “Drug Catalogue Adjustment Work Plan” includes drugs that are in urgent need of clinically needed overseas new drugs, encouraged generic drugs, or encouraged research and development to declare children’s drugs, and have been approved for marketing by the NMPA before August 17, 2020, and will be included in the 2020 drug list.
Increase the scope of drugs.
.
.

 

　　At present, our country's special medicines for children are mainly granules, tablets, and syrups.
There is a lack of dosage forms suitable for children, such as scored tablets, solutions, and suspensions.
According to industry insiders, when domestic pharmaceutical companies develop children's medicines, they may wish to consider innovating in dosage forms to meet changing market demands.
It is also a challenge for companies to develop dosage forms suitable for children's physiological characteristics .

 

　　Concluding remarks

 

　　According to the "Seventh National Census Communiqué" data, as of 2020, there are 253 million children aged 0-14 in my country, accounting for 18.
0% of the country's total population.
From the distribution of my country's new-born population, relevant experts currently say that the accumulation caused by family planning It will take about five years for the amount to be fully released, and the current children's drug market is far from being saturated.
On May 31, Xinhua News Agency reported that the "three-child birth" policy is also coming.
With the support of the national policy, my country's children's drug manufacturers will usher in more dividends and challenges in the future.

 

　　Source: Mynet database, Mynet's "my country Children's Drug Market Research Report (2021 Edition)"

　　Medical Network News, June 3, the annual "Children's Day" has arrived.
Under the influence of the epidemic in 2020, children's activities are basically limited to the two points and one line at home and school, plus the cross-infection of diseases after wearing masks The morbidity rate has been greatly reduced, and the parents' care is also more careful.
The children's resistance has improved, and the common diseases have been reduced correspondingly.
The market size of pediatric Chinese patent medicines ushered in a decline for the first time last year.
The market looks "depressed", but star pharmaceutical companies are still actively increasing their layout.
In the near future, Step Pharmaceutical plans to acquire Anyang Nuomei Pharmaceutical's exclusive variety Xiaoer Fuqi Zhixie San for 19 million yuan.
The company is expected to be in the field of pediatric Chinese patent medicines.
Add fierce generals.

 

　　The over 10 billion market has shrunk by nearly 3.
7 billion, but the retail subcategory has soared by 20%

 

　　Meinenet data shows that in 2020, the sales growth rate of pediatric Chinese patent medicines in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be -32.
34%.
The growth rate of the pharmacy terminal is -14.
94%, and the total market size has shrunk by nearly 3.
7 billion yuan from 2019.

 

　　Figure 1: The share of the seven subcategories of pediatric Chinese patent medicines in 2020 (unit: %)

　　Source: Mi Nei Net Database

 

　　In terms of subcategories, pediatric cold medications and pediatric cough and expectorant medications are the two subcategories with the largest proportions, both at the terminals of public medical institutions in China and physical pharmacies in cities in China, but they are also the two most affected by the epidemic.
Subcategory.
The growth rate of pediatric cold medicines in China's public medical institutions will be -36.
81% in 2020, and -19.
92% in physical pharmacies in Chinese cities; pediatric cold medicines will grow by -40.
12% in China's public medical institutions in 2020.
The growth rate of physical pharmacies in Chinese cities is -23.
32%.

 

　　Pediatric nutritional supplement medications have emerged in the physical pharmacies of Chinese cities.
The market share in 2020 is as high as 10.
88%, and the sales growth rate in the last three years is as high as 15.
46%, 14.
86%, and 20.
76%.

 

　　Figure 2: Sales of terminal pediatric nutritional supplements in physical pharmacies in cities in China (unit: 100 million yuan)

　　Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern

 

　　In recent years, with the improvement of living standards and the changes in people’s consumption outlook, more and more parents have begun to pay attention to children’s health issues, and they are paying more and more attention to children’s nutrition, and they are more willing to buy children’s growth.
Appropriate nutritional supplement products during the development process are conducive to the expansion of the pediatric nutritional supplement drug market; in addition, with the gradual refinement and improvement of prescription outflow policies, the full implementation in the future will further stimulate this category of products in the retail market Sales rose.

 

　　TOP10 products are exposed, these exclusive varieties are the most stress-resistant

 

　　Table 1: TOP10 products of pediatric Chinese patent medicine in 2020

　　Source: Mi Nei Net Database

 

　　In 2020, the threshold for the TOP10 products of pediatric Chinese patent medicines in public medical institutions in China is 130 million yuan (240 million yuan in 2019), and the only products exceeding 1 billion are Xiaoer Liaoqiao Qingre Granules; and the threshold for TOP10 pediatric Chinese patent medicines in Chinese urban physical pharmacies For 140 million yuan (160 million yuan in 2019), the sales of TOP1 product Longmu Zhuanggu pellets were 470 million yuan.

 

　　From the product point of view, Xiaoer Lianqiao Qingre Granules, Jinzhen Oral Liquid and Xiaoer Feire Kechuan Granules all appeared on the two lists.
It can be seen that these three products have become the backbone of the pediatric Chinese patent medicine market.
Among them, Jichuan Pharmaceutical’s exclusive product Xiaoer Liaoqiao Qingre Granules is as stable as Mount Tai.
This product is a large variety of over 1 billion, and it is mainly used to treat children with wind-heat and cold.
At present, the main battlefield is at the terminal of public medical institutions in China, under the background of the pressure of the environment.
, Still sits firmly on the TOP1 throne in 2020, and continues to maintain sales of about 300 million yuan in physical pharmacies in Chinese cities, and the TOP4 status remains unchanged.

 

　　Figure 3: The sales of Kaihoujian spray (child type) in the terminal of public medical institutions in China (unit: 100 million yuan)

　　Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

 

　　The sales of some products have achieved bucking growth.
At the terminal of public medical institutions in China, Guizhou Sanli Pharmaceutical’s Kai Throat Spray (children's type) is the only product on the TOP10 list with positive sales growth for three consecutive years.
This exclusive product is taken from the classic Miao medicine prescription.
Spray administration can directly act on the throat, tonsils and other lesions, reduce the liver burden of drug metabolism in children, and directly absorb, have fast onset, high curative effect, and short course of treatment.
Pharyngitis, tonsillitis, herpetic angina, oral ulcers and other common respiratory tract infections in children have obvious advantages.

 

　　Figure 4: Sales of Longmu Zhuanggu Granules in physical pharmacies in Chinese cities (unit: 100 million yuan)

　　Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern

 

　　In physical pharmacies in cities in China, Longmu Zhuanggu Granules, an exclusive product of Jianmin Pharmaceutical Group, has supported more than 90% of the market for pediatric supplementary nutrition drugs.
The sales growth rate from 2018 to 2020 is 16.
44% and 14.
54 respectively.
%, 20.
75%.
Longmu Zhuanggu granules are used to treat and prevent infantile rickets.
Jianmin Group mentioned in the annual report that in 2020, the company will vigorously promote lean production, control costs, improve quality, strengthen brand building, channel promotion, and optimize sales strategies to help realize products pay increment.

 

　　Although it is difficult to develop new drugs, Jichuan and Calabash are at the forefront

 

　　With the development of society and economy, the spectrum of children's diseases is constantly changing, but there is still a clear gap between the level of research and development of children's drugs in my country and the international level.
On the one hand, children’s drug clinical trials are very difficult, and the most prominent impact is the inability to recruit enough cases; on the other hand, there is a large gap in professional children’s drug clinical researchers, who are equipped with children’s medicine, pharmacy, nursing, ethics, Talents with knowledge and experience in psychology and other areas are obviously insufficient.
According to data from the MED2.
0 China Drug Evaluation Database of Meinenet , there are few pediatric Chinese patent medicines approved for marketing in recent years.
In 2019, Tasly and Fangsheng Pharmaceuticals were approved for one new drug, which is very encouraging in the industry.

 

　　Table 2: Status of pediatric Chinese patent medicine products approved for marketing in 2019

　　Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

 

　　Table 3: Some pediatric Chinese patent medicines that have been approved in the past five years and have started clinical trials

　　Source: China Drug Clinical Trial Publicity Library of Meinenet

 

　　Note: *is included in the priority review product

 

　　At present, a number of pediatric Chinese patent medicines under development have attracted the attention of the market: Xiao'er Soy Bean Curd is an exclusive product of Jichuan Pharmaceutical.
The granules that have been marketed have grown to over 1 billion products, and the syrup formulation is undergoing phase III clinical trials.
It is used for the syndrome of wind-heat and cold in children.

 

　　Another children’s drug star pharmaceutical company Hainan Huluwa Pharmaceutical Group also has a new drug in phase II clinical phase.
Xiaoer Malong Zhike Pingchuan Granules are intended to treat children with cough variant asthma (phlegm-heat accumulating lung syndrome); in addition, according to the company’s annual report It shows that Xiaoer Huaji Granules are also preparing for phase II clinical trials, which are intended to be used in children's digestion and Huaji related diseases.

 

　　Policy dividends help the growth of pediatric chemicals, and dosage form innovation will become a new trend

 

　　According to the "Research Report on my country’s Children’s Medicine Market (2021 Edition)" on Mynet, in the overall market of children’s medicines in my country, chemical drugs rely on their advantages of fast onset and clear mechanism of action.
In recent years, the market size has been rising.
The share has also increased to more than 60%, and the potential cannot be underestimated.

 

　　Several new policies were issued and implemented in 2020 to further stimulate the development of pediatric chemicals: The newly revised "Administrative Measures for Drug Registration" announced in March clearly stated that new varieties, dosage forms and specifications of children's drugs that meet the physiological characteristics of children can apply for priority Review and approval procedures; In June, CDE issued the "Guidelines for Pharmaceutical Development of Children's Drugs (Chemical Drugs) (Draft for Solicitation of Comments)" to provide R&D ideas and technical guidance for the pharmaceutical development of children's drugs; the "National Medical Insurance 2020" announced in August The “Drug Catalogue Adjustment Work Plan” includes drugs that are in urgent need of clinically needed overseas new drugs, encouraged generic drugs, or encouraged research and development to declare children’s drugs, and have been approved for marketing by the NMPA before August 17, 2020, and will be included in the 2020 drug list.
Increase the scope of drugs.
.
.

 

　　At present, our country's special medicines for children are mainly granules, tablets, and syrups.
There is a lack of dosage forms suitable for children, such as scored tablets, solutions, and suspensions.
According to industry insiders, when domestic pharmaceutical companies develop children's medicines, they may wish to consider innovating in dosage forms to meet changing market demands.
It is also a challenge for companies to develop dosage forms suitable for children's physiological characteristics .

 

　　Concluding remarks

 

　　According to the "Seventh National Census Communiqué" data, as of 2020, there are 253 million children aged 0-14 in my country, accounting for 18.
0% of the country's total population.
From the distribution of my country's new-born population, relevant experts currently say that the accumulation caused by family planning It will take about five years for the amount to be fully released, and the current children's drug market is far from being saturated.
On May 31, Xinhua News Agency reported that the "three-child birth" policy is also coming.
With the support of the national policy, my country's children's drug manufacturers will usher in more dividends and challenges in the future.

 

　　Source: Mynet database, Mynet's "my country Children's Drug Market Research Report (2021 Edition)"